OncoZenge (ONCOZ) Life Science Conference 2026 summary

Key insights from presentations

• BupiZenge aims to set a new standard for managing severe oral pain in cancer patients, addressing a significant unmet need in oral mucositis (OM) pain relief.

• Current OM pain treatments are inadequate, with 40% of patients experiencing severe pain despite best-in-class therapies; opioid use is common but problematic.

• BupiZenge offers rapid, long-lasting, non-opioid pain relief, potentially reducing opioid use and hospitalizations, and supporting better adherence to cancer therapy.

• The product leverages a well-known molecule (bupivacaine) in a lozenge form, with robust clinical and regulatory foundations.

Announcements and strategic plans

• 46.7 MSEK in financing secured for 2025, with a complete team and partnerships in place for Phase III execution and commercialization.

• Phase III Clinical Trial Application (CTA) submitted in December 2025, with EMA approval expected in April/May 2026 and first patient recruitment in Q2 2026.

• European launch targeted for 2028, with ambitions to reach one-third of OM patients and peak sales within six years.

• Licensing agreement with Molteni Farmaceutici covers Europe, providing R&D, financing, and commercial support, including royalties and milestones.

• Yangtian Pharma is engaged for rapid commercialization in China.

Industry analysis and market potential

• OM affects 35% of all cancer patients and up to 100% of head and neck cancer patients, representing a global revenue potential exceeding BSEK 10 annually.

• BupiZenge is positioned for a price premium over current treatments, with projected revenue per patient between SEK 3,000–12,000.

• Royalty revenue in Europe alone could reach 500 MSEK by 2034.

• Commercial rollout planned for 2028–2030 in Europe and adjacent markets, with ongoing efforts to secure US and China approvals.